Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Olumiant ® ▼ (baricitinib)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Olumiant Summary of Product Characteristics (SmPC)
Olumiant® ▼ (baricitinib): Laboratory Monitoring
Neutrophil, lymphocyte, hemoglobin, and hepatic transaminases levels should be assessed prior to initiation of baricitinib, and lipids should be assessed 12 weeks after initiation.
Laboratory Monitoring with Baricitinib Treatment
For information on laboratory monitoring with baricitinb treatment please see Table 1.
Table 1. Laboratory measures and monitoring guidance1
|
Laboratory Measure |
Action |
Monitoring Guidance |
|
Lipid parameters |
Patients should be managed according to international clinical guidelines for hyperlipidaemia |
12 weeks after initiation of treatment and thereafter according to international clinical guidelines for hyperlipidaemia |
|
Absolute Neutrophil Count (ANC) |
Treatment should be interrupted if ANC < 1 x 109 cells/L and may be restarted once ANC return above this value |
Before treatment initiation and thereafter according to routine patient management |
|
Absolute Lymphocyte Count (ALC) |
Treatment should be interrupted if ALC < 0.5 x 109 cells/L and may be restarted once ALC return above this value |
|
|
Haemoglobin (Hb) |
Treatment should be interrupted if Hb < 8 g/dL and may be restarted once Hb return above this value |
|
|
Hepatic transaminases |
Treatment should be temporarily interrupted if drug-induced liver injury is suspected |
Please refer to section 4.4 of the Olumiant Summary of Product Characteristics for further information on special warnings and precautions for use with baricitinib.
1. Olumiant [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Glossary
ALC = absolute lymphocyte count
ANC = absolute neutrophil count
BARI = baricitinib
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: November 13, 2020
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays